The Platelet Aggregation Devices Market Size was prized at USD 0.6 Billion in 2023 and is projected to grow from USD 0.70302 Billion in 2024 to USD 2.91 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 18.87% during the forecast period (2024 - 2032). Increased awareness and acceptance of platelet-related treatments for diseases, including cancer, are the key market drivers fostering the growth of the market. Technological developments in platelet aggregation are fueling the development of the market. Due to the increased demand for platelet screening programs to identify diseases like HIV and dengue, the market for platelet aggregation devices has expanded dramatically.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Market CAGR for platelet aggregation devices is driven by the rising number of people suffering from cardiovascular diseases. During the projected period, the prevalence of cardiovascular diseases (CVDs) is anticipated to rise globally, fueling the market for platelet aggregation devices. For instance, the use of platelet aggregation devices in managing CVD is predicted to raise demand for these devices globally. The World Health Organisation (WHO) estimates that CVDs claim 17.9 million lives annually, making them the leading cause of death and disability worldwide. This will therefore lead to increased demand for platelet aggregation devices globally.
The prevalence of bleeding diseases is anticipated to increase throughout the forecast period, fueling demand for platelet aggregation devices worldwide. Because platelet aggregation systems are used to diagnose bleeding problems, demand for them is rising along with the prevalence of bleeding disorders. A platelet aggregation test is typically administered to people who have bleeding issues. As per Centres for Disease Control and Prevention, 3 million Americans are thought to have a bleeding disorder. The need for platelet aggregation devices is then anticipated to rise due to this.
The increase in demand for platelet aggregation devices is anticipated to offer considerable potential prospects for market participants. For instance, the demand for platelet aggregation devices and the burden of chronic and bleeding illnesses are rising quickly. ADP MEA and TRAP-6 MEA were introduced in March 2020, according to Hart Bio. ADP MEA and TRAP-6 MEA are intended to track and test a patient's platelet aggregation function. ADP MEA is made to be used in whole blood for Multiple Electrode Aggregometry to diagnose platelet dysfunction or normal platelet activity.
The world's aging population is predicted to present companies in the market of platelet aggregation devices with significant growth prospects. For instance, aging increases the chance of chronic illnesses like cancer, diabetes, and heart disease. Additionally, many older adult bleeding problem patients are at risk for developing age-related comorbidities. The World Health Organisation (WHO) predicts that by 2030, one in six people will be over 60, and by 2050, there will be twice as many persons over 60 in the world (2.1 billion). Thus, driving the platelet aggregation devices market revenue.
The market segments of platelet aggregation devices, based on product, includes systems, reagents, consumables and accessories. In 2022, the Systems category is anticipated to hold the biggest market share. Due to factors like ongoing technological advancements in the field of sensors and detectors, the rising trend of automating platelet aggregation testing procedures, the growing adoption & market preference for automated instruments among diagnostic laboratories, and the increased patient compliance provided by point-of-care testing analyzers as compared to conventional instruments, this product segment is anticipated to grow at the highest CAGR over the next years.
July 2021:Baxter International, Inc. announced the completion of the acquisition of assets relating to the PerClot Polysaccharide Hemostatic System from CryoLife, Inc. through its Baxter Healthcare Corporation subsidiary. The PerClot Polysaccharide Hemostatic System is a supplementary hemostatic device used to control bleeding during various open and laparoscopic surgical operations, including gynecologic, general, cardiovascular, and urologic procedures.
Due to the rising need for reagents for platelet aggregation, it is anticipated that the reagents segment will experience considerable future growth. The reagents are chosen based on the approach used for platelet aggregometry.
The platelet aggregation devices market segmentation, based on application, includes clinical and research applications. Due to the rise in research and development, the research applications segment is anticipated to dominate the market over the forecast period and is expected to record the fastest growth rate. Platelet aggregation is used in numerous research projects, including toxicity and the screening of novel medical formulations.
The market segmentation of platelet aggregation devices, based on end-user, includes hospitals and clinics, diagnostic laboratories, and others. The hospitals and clinics segment controlled the market, accounting for 52.9% of market revenue (0.3 Billion) because of the rise in surgical procedures. In hospital procedures, platelet aggregation instruments are used to look for aberrant platelets. The increase in chronic diseases is expected to lead to significant growth in the diagnostic laboratories market in the near future.
Figure 1: Platelet Aggregation Devices Market, by End-User, 2023 & 2032 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
By region, the report gives market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American platelet aggregation devices market area will dominate this market due to the rise in the elderly population, rise in target disorders, technological developments in platelet aggregation meters, and a growing understanding among medical professionals of the advantages of platelet aggregation testing in disease detection.
Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.
Figure 2: PLATELET AGGREGATION DEVICES MARKET SHARE BY REGION 2023 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Europe’s platelet aggregation devices market accounts for the second-largest market share and is anticipated to be supported by the availability of inexpensive platelet function tests, expanding distribution channels, rising cardiovascular surgery rates, new technological advancements in platelet aggregators, and an increase in the number of clinical studies in the UK, Germany, and France. Further, the German market of platelet aggregation devices held the largest market share, and the UK market of platelet aggregation devices was the rapidly growing market in the European region.
The Asia-Pacific Platelet Aggregation Devices Market is expected to grow at a rapid rate from 2023 to 2032 due to factors including an aging population, an increase in chronic diseases, increased use of new technology, and an increase in mosquito-borne illnesses like malaria and dengue. Moreover, China’s market of platelet aggregation devices held the largest market share, and the Indian market of platelet aggregation devices was the rapidly growing market in the Asia-Pacific region.
Platelet Aggregation Devices Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the market of platelet aggregation devices, grow even more. To increase their worldwide footprint, market participants are also engaging in various strategic actions. Important market developments include introducing new products, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the platelet aggregation devices industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the platelet aggregation devices industry to benefit clients and increase the market sector. In recent years, the platelet aggregation devices industry has offered some of the most significant advantages to medicine. Major players in the platelet aggregation devices market, including Pathway Diagnostics Limited, Hoffmann-La Roche Ltd, Haemonetics Corporation, Helena Laboratories, Siemens Healthineers, and others, are attempting to increase market demand by investing in research and development operations.
Precision Biologics is a company that creates therapeutic medications to aid in the early detection and treatment of cancer. Clinicians can treat cancer patients using the company's monoclonal antibody medication candidates and diagnostics tools, which detect and target tumors without killing healthy cells. Controls and specialty plasmas, reagents, diagnostic kits, and customized solutions are all available from the company. In May 2022, Precision BioLogic Inc. announced the availability of their new CRYOcheck Chromogenic Factor IX assay in Canada, the European Union, the United Kingdom, Australia, and New Zealand, aftermarket approval by Health Canada and the corresponding in-country regulatory authorities. Precision BioLogic developed CRYOcheck Chromogenic Factor IX to fulfill the needs of today's clinical laboratories in response to the demand for chromogenic assays.
Cerus Corp is a biomedical goods firm specializing in blood transfusion safety. INTERCEPT platelet and plasma systems are sold in the United States of America, Europe, Commonwealth of Independent States countries, the Middle East, and a few other countries worldwide. In November 2022, Cerus Corporation reported that Health Canada had approved the storage of platelets treated with the INTERCEPT Blood System for seven days from the time of collection, joining other areas where INTERCEPT platelets are approved for seven days. To lessen the chance of infections being spread during transfusions, the INTERCEPT Blood System is made to inactivate various pathogens, including bacteria, viruses, and parasites.
Key Companies in the platelet aggregation devices market include
Siemens Healthineers
Hoffmann-La Roche Ltd
Sysmex Corporation
Werfen
Bio/Data Corporation
AggreDyne, Inc.
Haemochrom Diagnostica GmbH
Pathway Diagnostics Limited
Platelet Aggregation Devices Industry Developments
November 2023: Sysmex Corporation launches its new CN-8000, a fully automated platelet aggregation analyzer that offers high throughput and accuracy. The CN-8000 is designed to help laboratories meet the increasing demand for platelet aggregation testing, and it features a number of new features, including a new optical system that provides high-resolution images of platelets.
October 2023: HORIBA, Ltd. announces the launch of its new PentraCell 800, a compact and affordable platelet aggregation analyzer that is ideal for small laboratories and clinics. The PentraCell 800 features a number of advanced technologies, including a new optical system and a new software algorithm, which enable it to provide accurate and reliable results.
September 2023: LFA Biosystems, Inc. announces the launch of its new PlateletWorks analyzer, a next-generation platelet aggregation analyzer that features a number of innovative features, including a new microfluidic system that enables rapid and accurate testing. The PlateletWorks analyzer is designed to help researchers and clinicians gain a better understanding of platelet function and to develop new and more effective treatments for platelet disorders.
August 2023: Diagnostica Stago, S.A. announces the launch of its new STA-R Max2 analyzer, a fully automated hemostasis analyzer that features a number of new tests, including a platelet aggregation test. The STA-R Max2 analyzer is designed to help laboratories improve the efficiency and accuracy of their hemostasis testing.
July 2023: Thermo Fisher Scientific, Inc. announces the launch of its new Acclaim 1000 platelet aggregation analyzer, a fully automated platelet aggregation analyzer that offers high throughput and accuracy. The Acclaim 1000 analyzer is designed to help laboratories meet the increasing demand for platelet aggregation testing, and it features a number of new features, including a new software algorithm that enables rapid and accurate results.
Systems
Reagents
Consumables And Accessories
Clinical
Research Applications
Hospitals and Clinics
Diagnostic Laboratories
Others
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.6 Billion |
| Market Size 2024 | USD 0.7302 Billion |
| Market Size 2032 | USD 2.91 Billion |
| Compound Annual Growth Rate (CAGR) | 18.87% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Market Competitive Landscape, Revenue Forecast, Growth Factors, and Trends |
| Segments Covered | Product, Application, and End-User |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil. |
| Key Companies Profiled | Pathway Diagnostics Limited, Hoffmann-La Roche Ltd, Haemonetics Corporation, Helena Laboratories, and Siemens Healthineers |
| Key Market Opportunities | Technological advancements in platelet aggregometer |
| Key Market Dynamics | Rising incidence of chronic diseases |
Platelet Aggregation Devices Market Highlights:
Frequently Asked Questions (FAQ) :
The market size of platelet aggregation devices market was valued at USD 0.5 Billion in 2022.
The worldwide market is forecast to expand at a CAGR of 18.87% from 2024 to 2032.
North America had the largest share of the market.
The key players in the market are Pathway Diagnostics Limited, Hoffmann-La Roche Ltd, Haemonetics Corporation, Helena Laboratories, and Siemens Healthineers.
The system category dominated the market in 2022.
The research applications had the largest share of the market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
